Navigation Links
Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer
Date:8/22/2014

LA JOLLA, Cali., Aug. 22, 2014 /PRNewswire/ -- Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer.

When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise T. Chow, Ph.D. and Thomas Broker, Ph.D., who presented the findings at the Seattle conference. The National Institute of Allergy and Infectious Diseases in the National Institutes of Health funded Chow's work at the University of Alabama, Birmingham.

"HTI-1968 is potent and selective, inhibiting the growth of these high-risk HPV types. Dr. Chow's findings, though early stage, offer hope to millions of women infected by one of these high-risk HPV types, including two that are responsible for 70 percent of cervical cancer cases," said Hera Therapeutics CEO Karl Hostetler, M.D.. Currently surgery is the only therapy available to women who have persistent infection with these types of HPV and show signs of abnormal cells.

Hera Therapeutics is developing a topical, non-surgical approach to treat HPV, which could alter the standard of care while preserving structural integrity of the cervix.

Approximately 96 million people worldwide, men and women, are infected with HPV-16 or HPV-18, according to the Centers for Disease Control. Almost 4,000 women in the U.S. die from invasive cervical cancer each year, according to the CDC.

While cervical cancer vaccines prevent infection from the disease, they are not approved by the FDA for marketing to people over 26-years-old and have not demonstrated efficacy in people already infected with the HPV virus.

About Hera Therapeutics Inc.

Using a new medicinal chemistry platform, Hera Therapeutics Inc. is focused on the research, development and commercialization of direct acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV and animal retroviruses.

Hera Therapeutics was founded in 2012 by Karl Hostetler, M.D., a professor emeritus at University of California, San Diego, who was previously a founder of three biotech companies, including Chimerix, Triangle Pharmaceuticals and Vical.


'/>"/>
SOURCE Hera Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
2. Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite
3. Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
4. Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
5. FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
6. TRU-D Tested in Most Comprehensive UV Disinfection Study to Date
7. Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
8. R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
9. Study: 1 out of 5 adult orthopaedic trauma patients sought additional providers for narcotic prescriptions
10. Study Helps Medical Education Leaders Navigate the New Regulatory and Financial Landscape
11. BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2018)... ANGELES (PRWEB) , ... September 01, 2018 , ... Dr. ... dentistry, oral surgery, and orthodontic treatment he has been offering patients for twenty years ... all of the dental services they are likely to need under a single roof. ...
(Date:8/31/2018)... Tenn. (PRWEB) , ... August 31, 2018 , ... ... that Onlife Health, a national company with 22 years of expertise in delivering ... first Healthy Behavior Data Challenge (HBDC).  , Onlife Health will receive a $40,000 ...
(Date:8/31/2018)... ... August 31, 2018 , ... After ... be a painful process for many. , “Prolonged weeks of going barefoot and ... podiatric foot and ankle specialist Adam Howard, DPM. , “Heel pain and arch ...
Breaking Medicine Technology:
(Date:8/31/2018)... ... 31, 2018 , ... Nitro Circus hosted the inaugural A Night to Live ... sports gathering to celebrate the life of Erik Roner, world-renowned skier, skydiver and a ... Annika and their two small children, Oskar (8) and Kasper (4). A portion of ...
(Date:8/31/2018)... ... August 31, 2018 , ... NJ Top ... for another year. Dr. Savon has been active in gastrointestinal research for many ... care for all gastrointestinal diseases and disorders for the past 25 years. , ...
(Date:8/31/2018)... CAMARILLO, Calif. (PRWEB) , ... August 31, 2018 ... ... microbatteries, is pleased to announce the promotion of Nitin Arneja to Chief Information ... role will lead the efforts to develop technology solutions that protect, optimize, scale, ...
(Date:8/29/2018)... ... 2018 , ... Shady Grove Fertility (SGF), with now five locations ... relocating two of their offices this September. Their Harrisburg, PA office is ... located on the campus of UPMC PinnacleHealth Fredericksen Outpatient Center. , The practices ...
(Date:8/29/2018)... ... August 29, 2018 , ... ... learn, socialize or communicate with others. Physically, it is not possible to identify ... with problems may be challenged. People with autism may need assistance in developing ...
Breaking Medicine News(10 mins):